Sartorius Stedim Biotech Shares Bounce to €162.30 Despite a 19% Decline Over the Year
The French bioproduction equipment specialist is moving forward in mid-morning trading. The Sartorius Stedim Biotech stock is up 2.4% at €162.30, in an SBF 120 that is up 0.77%. This movement extends the rebound that began yesterday, without erasing the 19% decline accumulated over the year.
A 2.4% Rebound Under Still Bearish Moving Averages
The stock is up 2.4% to €162.30, from €158.50 the previous day. This increase continues the rebound of 3.85% recorded on Monday, already supported by a well-oriented Parisian market. The technical setup remains degraded. The price is moving below its three moving averages: MM20 at €164.03, MM50 at €167.31, and MM200 at €185.30. The gap with the 200-day average reaches 12.4%, indicating that the medium-term momentum remains unfavorable despite the recovery in the last two sessions. The RSI at 44 remains in the neutral zone, and the price is positioned in the middle of the Bollinger bands (46%), far from the lower boundary at €143.29 which had served as a turnaround zone at the end of April.
A Stretched Valuation at 32 Times Earnings, Next Meeting on July 23
On the fundamental front, the stock is trading at about 32.1 times the expected earnings for the current fiscal year and 26.8 times those of 2027, based on a consensus of ten analysts. The average for the healthcare sector in Europe is around 22.2 times. The expected year-over-year earnings per share growth is set at 20%, which partly justifies this sector premium. As a reminder, the first quarter 2026 revenue published on April 23 had reached €762 million, up 7.9% at constant exchange rates, but with a slight decline in current EBITDA margin to 30.7%. The market reaction was immediate, with the stock touching €153 at the end of April due to margin pressure and customs context. The next appointment is scheduled for July 23, 2026, with the publication of the half-year results.
